Please assess the completion status of the following clinical trial:

Trial Title: Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* PD group：~  * Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria~ * Newly diagnosed primary PD patients, diagnosed within 3-6 months~ * Informed consent to the study~ * Age \> 18 older~* Non-PD group:~  * Age, gender-matched PD group~ * Non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history~ * Informed consent to the study~ * Age \> 18 older~Exclusion Criteria:~* Severe craniocerebral trauma patients~* Disturbance of consciousness~* Severe organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment~* History of severe brain tumors, encephalitis or brain surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Parkinson's disease group (Type: None): 1. Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~2. Newly diagnosed primary PD patients, diagnosed within 3-6 months;~3. informed consent to the study;~4. age \> 18 older.
- Non-parkinson group (Type: None): Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age \> 18 older.

Based on this trial design, predict the completion outcome and termination type (if applicable).